Salute e Benessere

Azazie Makes a Statement at London's National Wedding Show with Bold Bridal…

Azazie redefined what bridal looks like in 2025. Across six high-energy catwalk shows, the brand debuted everything from sweeping fairytale gowns to clean-cut modern silhouettes, tailored bridal pantsuits, and bridesmaid dresses in vibrant hues. This season's focus? Celebrating self-expression. Every look was designed with today's bride in mind. Azazie redefined what bridal looks like in 2025. Acrosssix high-energy catwalk shows, the brand debuted everything from sweeping fairytale gowns to...
PR Newswire
21/04/2025

Cell Based Assays Market worth US$27.55 billion by 2030 with 9.1% CAGR |…

Browse in-depth TOC on "Cell Based Assays Market" Browse in-depth TOC on "Cell Based Assays Market" 560 - Tables 62 - Figures 460 - Pages By Based on segment,in 2024, pharmaceutical & biopharmaceutical companies led the cell-based assays market. This growth is primarily driven by the increasing demand for drug discovery and development, particularly due to the rising prevalence of cancer. The growing number of research & development activities aimed at creating new...
PR Newswire
21/04/2025

LILYSILK Unveils Summer 2025 Collection "Island Ease," Blending Military Chic…

"Island Ease" encourages wearers to slow down and reconnect—with nature, travel, and themselves. Inspired by the natural beauty of Majorca, the collection features earthy tones and subtle prints that reflect the island's warmth and charm. Each design combines structure and softness, blending tailored details like sharp lapels and clean lines with lightweight, breathable fabrics. The result is a versatile wardrobe that transitions easily from day to night, offering comfort and…
PR Newswire
21/04/2025

The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New…

The study, "Regulatory T Cell Epitope Content in Human Antibodies Decreases During Maturation", was conducted by Andres Gutierrez, PhD and Annie De Groot, MD of EpiVax, using existing antibody sequence data. "This work provides important insights into how antibodies evolve over time, not just in terms of affinity, but in their ability to engage with the immune system." said Dr. Gutierrez. The study," Regulatory T Cell Epitope Content in Human Antibodies Decreases During…
PR Newswire
21/04/2025

INTCO Medical Launches New Syntex™ Synthetic Disposable Latex Gloves Featuring…

Unlike traditional latex gloves, the new Syntex™ gloves offer high elasticity, strong puncture and chemical resistance, and a natural-latex-like feel, all while avoiding the allergy risks associated with natural latex. Developed with an exclusive innovative formula that increases average breaking elongation through a 650% stretch, meeting the ASTM D6319 medical glove standard and offering exceptional durability and comfort. Unlike traditional latex gloves, the new Syntex™ gloves offer high...
PR Newswire
21/04/2025

Rona Therapeutics Announces NMPA Approval of IND Application for RN1871, a Novel…

Stella Shi, CEO and Founder of Rona Therapeutics, stated: "The IND approval of RN1871 marks a significant breakthrough in our pursuit of innovative therapies for chronic diseases. By leveraging siRNA technology to treat disease fundamentally, RN1871 achieves sustained efficacy with less dosing frequency. We look forward to bringing this innovative therapy to hypertension management where more compliant and safe treatment is needed to improve cardiovascular events and other…
PR Newswire
21/04/2025

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

LONDON and PHOENIX, Ariz., April21, 2025(GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 5,000 ACUT shares in the open market. This brings his total holding to 4,915,759 shares. About AccuStem AccuStem is a clinical stage diagnostics company dedicated...
Nasdaq GlobeNewswire
21/04/2025

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical…

“Dr. Mekan brings a combined 18 years of experience in hematology and oncology across academic research, clinical practice and biopharmaceutical industry development, and I am excited to welcome her to our team,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “Her expertise in both early and late phase oncology development and proven track record of leading submissions and interactions with global regulatory agencies will be instrumental as we advance our 5x5...
Nasdaq GlobeNewswire
21/04/2025

Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset…

Positioning of Diamyd® Positioning of Diamyd ® Diamyd® is a precision immunotherapy targeting individuals with a specific HLA genotype associated with Type 1 Diabetes. Over 1,000 patients have been treated with Diamyd® , a durable investigational antigen-specific GAD-based therapy, giving it a robust safety track record. The treatment aims to preserve endogenous insulin production by reprogramming the immune system-addressing the root cause of the disease rather than just managing...
PR Newswire
21/04/2025

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug…

The abstract of the presentation is available at https://www.abstractsonline.com/pp8/#!/20273/presentation/3006. The abstract of the presentation is available at https://www.abstractsonline.com/pp8/#!/20273/presentation/3006. More information about the AACR Annual Meeting 2025 can be found on the event website at the following link:AACR Annual Meeting 2025 | Meetings | AACR About K-679 K-679 is an Antibody Drug-loaded Unimicelle Conjugate (ADUC), a novel type of ADC using...
PR Newswire
21/04/2025

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom

CASGEVY became the world's first genome editing therapy to receive marketing authorization, beginning with the United Kingdom in November 2023, followed by the European Commission (EC) in February 2024. It provides a novel treatment for patients with sickle cell disease and beta-thalassemia. The one-time treatment is reportedly priced at approximately £1.7 million (approx. $2.2 million USD), with sales projections indicating blockbuster potential. In December 2023, Vertex entered into a…
PR Newswire
21/04/2025

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCopenhagen, Denmark, April 19, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's…
Nasdaq GlobeNewswire
19/04/2025

Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board…

Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025Copenhagen, Denmark, April 19, 2025– Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the implementation of long-term incentive programs for 2025 (the “LTIP”)…
Nasdaq GlobeNewswire
19/04/2025

IBA – ACQUISITION OF OWN SHARES

Immediate Release – April 18 th, 2025 Louvain-la-Neuve, Belgium, April 18 th, 2025 -In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24 th, 2025. Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the...
Nasdaq GlobeNewswire
18/04/2025

Declaration on longevity and precision medicine launched at Abu Dhabi Global…

Speaking at the launch, H.E. Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH) stated: "Healthy populations lead to healthy communities, stronger social cohesion, and fuels economic growth. This declaration unites global leaders to harness emerging technologies responsibly and deliver the benefits of precision medicine to all. Because health knows no boundaries, we are working together towards actionable and long-term solutions." Speaking at the…
PR Newswire
18/04/2025

Yarbo Secures $27M+ Series B Funding to Accelerate Global Growth, Innovation…

A Decade of Innovation, One Yard at a Time A Decade of Innovation,One Yardat a Time Founded in 2015, Yarbo began life as Snowbot: targeting the infamously tough task of snow removal, a long-standing pain point for homeowners. Since then, the company has transformed from a niche robotics brand into aglobal category leader in outdoor automation, now operating under the Yarbo name. With its signature"1+N" modular design, Yarbo offers year-round functionality powered by one...
PR Newswire
18/04/2025

Press Release: Dupixent approved in the US as the first new targeted therapy in…

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and...
Nasdaq GlobeNewswire
18/04/2025

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine…

Saint Herblain (France), April 18, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ ®for the prevention of disease caused by the chikungunya virus (CHIKV). ACIP maintained its current...
Nasdaq GlobeNewswire
18/04/2025

Alis Biosciences launches fund to free over USD$30 billion of capital trapped in…

Alis offers public companies a range of innovative and adaptable structures to return capital to their shareholders, while providing a chance for any residual science and IP to be developed if appropriate. Alis will approach the board and management of each target company and mutually agree the optimum Alis structure to deploy. Alis will then seek to delist the company from the public market with the agreement of its shareholders in the normal way. Each delisted company's cash and IP will be…
PR Newswire
18/04/2025

Casino Group: Dutch court approves buy-out of minority shareholders of Cnova…

Dutch court approves buy-out of minority shareholdersof Cnova N.V. Paris, France / Amsterdam, the Netherlands, 18 April 2025 Casino, Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR001400OKR3) (“ Casino ”) hereby announces the following:Euronext Paris has informed Cnova N.V. (ISIN: NL0010949392) (“ Cnova ”) and Casino, that the request for the delisting of the Cnova shares has been approved : the delisting will be effective as of the date of completion of the Mandatory Buy-Out...
Nasdaq GlobeNewswire
18/04/2025

TRYVIO/JERAYGO Positioned to Redefine Treatment of Resistant Hypertension |…

Idorsia Pharmaceuticals' TRYVIO/JERAYGO (aprocitentan) Overview Idorsia Pharmaceuticals' TRYVIO/JERAYGO (aprocitentan) Overview TRYVIO is a once-daily oral medication that acts as a dual endothelin receptor antagonist, blocking the binding of endothelin-1 (ET-1) to both ETA and ETB receptors. This mechanism makes it particularly effective for reducing blood pressure in adults whose hypertension remains uncontrolled with other treatments. TRYVIO also has a low risk of drug-drug interactions...
PR Newswire
17/04/2025

FYARRO Sets New Standard in Rare Oncology Market with Strong Growth Prospects |…

Whitehawk Therapeutics' FYARRO (sirolimus protein-bound/ABI-009) Overview Whitehawk Therapeutics' FYARRO (sirolimus protein-bound/ABI-009) Overview FYARRO (albumin-bound) is a targeted therapy approved for the treatment of adults with locally advanced unresectable or metastatic malignant PEComa. This medication is specifically designed to combat cancer by targeting abnormal growth signals in perivascular epithelioid cells, which multiply uncontrollably in advanced PEComa. By blocking a key...
PR Newswire
17/04/2025

Alkermes to Report First Quarter Financial Results on May 1, 2025

About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a…
PR Newswire
17/04/2025

Burnett Homeopathy Private Limited Convenes Global Experts at World Homoeopathy…

The Scientific Society for Homoeopathy, Köthen, renders homage through a special luncheon, offering an occasion for international delegates to warmly and informally network and collaborate. Furthermore, the summit was full of exciting activities, including a unique trip to the birthplace and practice of Dr Hahnemann, an event greatly deepened into the history of classical Homoeopathy for the participants. This was followed by a knowledge-exchange program and presentation of case studies to…
PR Newswire
17/04/2025
Altri  Comunicati